A Shared Opportunity: The Future Of Cell And Gene Therapy

By Anshul Mangal and Philip Cyr, Sr.

Despite the many challenges of the last two years, the global cell and gene therapy (CGT) market continues to rapidly expand. The investment landscape for regenerative medicine has grown 16% in 3 years, hitting an all-time high in 2021 of $23.1 billion raised. With more funding pouring in each year and over 2,261 ongoing global clinical trials in regenerative medicine, the market is expected to reach $34.31 billion in 2030. With this immense growth potential, the industry is reaching a tipping point heading towards commercialization. Cell and gene therapies provide hope for many patients suffering from rare diseases, creating great urgency to bring these treatments to market.

The commercialization of CGTs forces several complex economical conversations and questions, some concerns include manufacturing, labor challenges, payer coverage, adequate reimbursement, and cost-effectiveness. To find adequate solutions, we must first have a deep understanding of the process and factors driving the high-ticket price of these life-saving therapies.